In vitro activity of immunosuppressive agents against Cryptococcus neoformans.
Amphotericin B
Anfotericina B
Ciclosporina A
Cryptococcus spp.
Cyclosporine A
Sinergia
Synergism
Tacrolimus
Journal
Enfermedades infecciosas y microbiologia clinica (English ed.)
ISSN: 2529-993X
Titre abrégé: Enferm Infecc Microbiol Clin (Engl Ed)
Pays: Spain
ID NLM: 101777541
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
10
07
2020
accepted:
19
09
2020
entrez:
5
2
2022
pubmed:
6
2
2022
medline:
11
3
2022
Statut:
ppublish
Résumé
Infections caused by Cryptococcus neoformans are a major cause of fungal mortality in HIV-infected/AIDS patients and in those receiving organ transplants. We evaluated the in vitro activity of tacrolimus and cyclosporine in combination with amphotericin B and fluconazole against C. neoformans. MICs were determined against a total of 30 clinical isolates of C. neoformans by the microdilution method following the CLSI M27-A3 guidelines and by the checkerboard method. Tacrolimus and cyclosporine A showed in vitro activity against cryptococcal isolates. The combination of amphotericin B with cyclosporine A or tacrolimus was synergistic against 90% and 30% of isolates, respectively. Synergism was also observed with the combination of fluconazole with cyclosporine A or tacrolimus, against 70% and 20% of isolates, respectively. The synergistic interactions between the calcineurin inhibitors and antifungal drugs against C. neoformans isolates, could potentially have a role in devising novel therapeutic strategies for this opportunistic mycosis.
Identifiants
pubmed: 35120653
pii: S2529-993X(22)00005-3
doi: 10.1016/j.eimce.2020.09.007
pii:
doi:
Substances chimiques
Antifungal Agents
0
Immunosuppressive Agents
0
Fluconazole
8VZV102JFY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
86-88Informations de copyright
Copyright © 2020 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.